Danaher Q1 Revenues Increase 11 Percent | GenomeWeb

The story has been updated to include comments from Danaher's CEO.

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Danaher today reported an 11 percent rise in first-quarter sales with its Life Sciences and Diagnostics segment jumping 22 percent.

For the three months ended April 1, the Washington-based conglomerate said that total sales came in at $3.35 billion, compared to $3.01 billion the year before. Wall Street had a consensus estimate of $3.32 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.